venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences - read this article along with other careers information, tips and advice on BioSpace
venBio Closes Venture Capital Fund Focused on Life Sciences, At $550M
venBio, a Palo Alto, CA and San Francisco, CA-based closed its fourth life sciences venture capital fund, venBio Global Strategic Fund IV, LP, at approximately $550m.
The capital was raised from existing and new investors, including a broad range of institutional investors comprising corporate pensions, financial institutions, university endowments and foundations, family offices and funds-of-funds.
Led by Managing Partners Corey Goodman, Ph.D., Robert Adelman, M.D., Aaron Royston, M.D., and Richard Gaster, M.D., Ph.D., venBio Fund IV will continue to invest primarily in therapeutics companies that are developing biopharmaceuticals for unmet medical needs. The venBio team takes an active role with each of their portfolio companies, providing strategic guidance on a range of business activities including intellectual property, chemistry, manufacturing and controls (CMC), as well as assisting with clinical trials